CDMOs manufacturing for both US and EU markets are inspected by two different regulatory systems, not one. FDA inspections follow one set of rules. EMA and national competent authority (NCA) inspections follow another. The differences show up in notice, frequency, findings classification, and escalation.

The EU-US Mutual Recognition Agreement (MRA) has narrowed that gap, but it hasn’t closed it. Knowing exactly where the overlap ends is what separates genuine dual-jurisdiction readiness from an assumption that one agency’s approval speaks for both.

How do FDA and EMA inspections differ for CDMOs?

FDA and EMA/NCA inspections are built on different logic. One runs on a fixed surveillance cycle with formal, documented findings. The other is triggered more by specific applications or concerns, and often stays conversational until the final written report. Here’s how the two compare, aspect by aspect:

Aspect FDA EMA
Trigger & frequency Routine surveillance roughly every 2 to 3 years, plus unannounced, for-cause and application-based inspections. Frequency varies by national competent authority (NCA); often triggered by a marketing authorization application or a specific product concern rather than a fixed cycle.
Notice Formal: credentials and Form 482 presented at the start of the visit. Increasingly unannounced for foreign sites. Typically a short verbal notice outlining purpose, documents and key personnel. Exact approach varies by NCA.
Findings Form 483 observations, classified No Action Indicated, Voluntary Action Indicated, or Official Action Indicated. Formal inspection report. Non-compliance areas are usually discussed verbally in a closing meeting before the written report follows.
Escalation Warning letters, import alerts, consent decrees. GMP non-compliance reports logged via EudraGMDP. Potential certificate suspension or withdrawal.
Who inspects FDA investigators, unless a recognized authority’s results are accepted under the MRA. The NCA of the member state where the site is located, unless a joint EU inspection applies.

 

What does the EU-US Mutual Recognition Agreement change?

The MRA lets each side rely on the other’s GMP inspection results instead of duplicating them. It has been operational since November 2017, and veterinary products reached full operational status in May 2026. EU authorities have also been able to rely on FDA inspections conducted outside US territory since October 2025.

The MRA doesn’t remove either agency’s authority, though. Two limits matter for CDMOs planning their inspection readiness:

  • Both regulators retain the right to inspect in each other’s territory at any time.
  • The MRA explicitly excludes vaccines, plasma-derived products, blood and tissue products, and investigational medicinal products. CDMOs running clinical-stage or IMP manufacturing remain fully exposed to inspection by both agencies, regardless of the MRA.

Why FDA’s expanded unannounced foreign inspections raise the stakes for European CDMOs

The FDA has expanded its use of unannounced inspections at foreign facilities, and the reasoning behind that shift matters as much as the fact of it:

  • Advance warning gave facilities time to carry out ‘just-in-time’ clean-ups, falsify paperwork, or temporarily hide issues ahead of the inspection.
  • An agency performance summary found that 45% of foreign inspections uncovered data integrity issues or failures to meet basic current Good Manufacturing Practice standards.
  • The shift also brings administrative parity between US and EU manufacturers, who have historically faced different notice practices.

FDA and EMA share findings and intelligence with each other. A poor outcome with one regulator can prompt scrutiny from the other, which means treating the two as separate risk tracks is no longer a safe assumption. Regulatory enforcement trends increasingly move across agencies, not just within them.

What does inspection readiness look like for a CDMO working across both markets?

Inspection readiness that works for both regulators looks less like two separate playbooks and more like one system built to hold up under either one. It builds on the fundamentals covered in what is inspection readiness and GxP audit and inspection readiness, applied consistently across jurisdictions:

  • Continuous documentation and data integrity practices, maintained as a standing discipline rather than assembled ahead of a known visit.
  • Mock inspection programs that prepare teams for both the FDA’s formal, document-led style and the more conversational style used by national competent authorities.
  • A single quality system and CAPA process that can produce evidence quickly, regardless of which regulator is asking.

What should sponsors look for when qualifying a CDMO on inspection readiness?

Sponsor-side quality and vendor oversight teams assessing a CDMO’s dual-jurisdiction readiness should look past a single audit and ask about the full inspection history and posture:

  • FDA 483s and warning letters
  • EU GMP non-compliance reports and EudraGMDP status
  • What mock inspections look like, and how frequently they run
  • Documentation and data integrity maturity
  • Evidence of readiness for both regulators, not just the one that inspected most recently

How Infodesk supports CDMO inspection readiness across jurisdictions

Staying ready for both agencies starts with seeing both agencies clearly. Infodesk brings together:

  • FDA and EMA/NCA enforcement actions
  • Guidance updates
  • Inspection trends

Users can access all of this information in one place, side by side, through Infodesk’s inspection and enforcement intelligence solution. That intelligence is routed directly to the CDMO or sponsor stakeholders who need to act on it, so the people responsible for readiness see the same evidence at the same time.

Inspection and enforcement intelligence. Activated.

Dual-jurisdiction inspection readiness depends on seeing the full picture, not just the half that lands on your desk. Book a meeting to see how Infodesk brings FDA and EMA/NCA intelligence together for your team.

More resources

Read more about inspection & enforcement intelligence